ACL
SMMT icon

APEIRON Capital Ltd’s Summit Therapeutics SMMT Stock Holding History

APEIRON Capital Ltd’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Sell
961,866
-347,275
-27% -$6.16M 9% 5
2026
Q1 		$24.8M Sell
1,309,141
-100
-0% -$1.62K 23.21% 2
2025
Q4 		$22.9M Sell
1,309,241
-1,700
-0.1% -$32K 26.48% 2
2025
Q3 		$27.1M Buy
1,310,941
+110,000
+9% +$2.67M 12.87% 3
2025
Q2 		$23.2M Buy
+1,200,941
New +$27.4M 21.87% 3

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

APEIRON Capital Ltd's SMMT Position: Q2 2026 in Review

APEIRON Capital Ltd reduced its Summit Therapeutics (SMMT) stake by 27% in Q2 2026, selling an estimated $6.16M and leaving 961,866 shares worth $14M. The position accounts for 9% of the portfolio, ranked #5.

APEIRON Capital Ltd first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $27.1M in Q3 2025. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • APEIRON Capital Ltd held 961,866 shares of Summit Therapeutics worth $14M as of Q2 2026.
  • APEIRON Capital Ltd sold 347,275 Summit Therapeutics shares in Q2 2026, an estimated $6.16M.
  • Summit Therapeutics made up 9% of APEIRON Capital Ltd's portfolio in Q2 2026, its #5 holding.
  • APEIRON Capital Ltd first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • APEIRON Capital Ltd's Summit Therapeutics position peaked at $27.1M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on APEIRON Capital Ltd's 13F filing for Q2 2026, filed 6 Aug 2026.